These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 28190703

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Rixe O, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Molinié V, Escudier B.
    Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A, Hamid AR, Mochtar CA, Umbas R.
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors.
    Rua Fernández OR, Escala Cornejo R, Navarro Martín M, García Muñoz M, Antunez Plaza P, García Dominguez AR, Cruz Hernández JJ.
    Urology; 2018 Jul; 117():41-43. PubMed ID: 29702156
    [Abstract] [Full Text] [Related]

  • 7. [Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
    Ivanyi P, Grünwald V.
    Aktuelle Urol; 2015 Nov; 46(6):467-72. PubMed ID: 26556569
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New options for second-line therapy of advanced renal cancer.
    Bex A.
    Lancet Oncol; 2013 May; 14(6):450-1. PubMed ID: 23598169
    [No Abstract] [Full Text] [Related]

  • 12. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A.
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [Abstract] [Full Text] [Related]

  • 13. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.
    Liu YC, Chang PM, Liu CY, Yang CY, Chen MH, Pan CC, Chen MH.
    Jpn J Clin Oncol; 2011 Nov; 41(11):1277-81. PubMed ID: 21965162
    [Abstract] [Full Text] [Related]

  • 14. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Alasker A, Meskawi M, Sun M, Ismail S, Hanna N, Hansen J, Tian Z, Bianchi M, Perrotte P, Karakiewicz PI.
    Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
    [Abstract] [Full Text] [Related]

  • 15. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK, Gandhi S, George S.
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [Abstract] [Full Text] [Related]

  • 16. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
    van der Zanden LFM, Vermeulen SH, Oskarsdottir A, Maurits JSF, Diekstra MHM, Ambert V, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia Donas J, Guarch Troyas R, Guchelaar HJ, Hartmann A, Hulsbergen-van de Kaa C, Jaehde U, Junker K, Martinez-Cardus A, Masson G, Oosterwijk-Wakka J, Radu MT, Rafnar T, Rodriguez-Antona C, Roessler M, Ruijtenbeek R, Stefansson K, Warren A, Wessels L, Eisen T, Kiemeney LALM, Oosterwijk E.
    Urol Oncol; 2017 Aug; 35(8):529.e9-529.e16. PubMed ID: 28385611
    [Abstract] [Full Text] [Related]

  • 17. Clinical management of metastatic kidney cancer: the role of new molecular drugs.
    Vitale MG, Cartenì G.
    Future Oncol; 2016 Jan; 12(1):83-93. PubMed ID: 26617188
    [Abstract] [Full Text] [Related]

  • 18. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H, Imai S, Harada K, Fujisawa M.
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
    Ouzaid I, Bensalah K.
    Eur Urol; 2015 Sep; 68(3):542-3. PubMed ID: 26001611
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.